EntreMed reels as Bristol halts work on cancer drug
Bristol-Myers Squibb Co.'s decision to halt development of its high-profile cancer drug angiostation deals a blow to the efforts of tiny biotech company EntreMed Inc. and Harvard scientist Judah
Bristol-Myers Squibb Co.'s decision to halt development of its high-profile cancer drug angiostation deals a blow to the efforts of tiny biotech company EntreMed Inc. and Harvard scientist Judah